FSCN1 Promotes Radiation Resistance in Patients With PIK3CA Gene Alteration

Radiotherapy is one of the standard treatments for cervical cancer and head and neck cancer. However, the clinical efficacy of this treatment is limited by radioresistance. The discovery of effective prognostic biomarkers and the identification of new therapeutic targets have helped to overcome the...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in oncology Vol. 11; p. 653005
Main Authors:	Li, Sisi, Huang, Xiao-ting, Wang, Meng-yao, Chen, Dong-ping, Li, Ming-yi, Zhu, Yan-yi, Yu, Yi, Zheng, Lu, Qi, Bin, Liu, Jin-quan
Format:	Journal Article
Language:	English
Published:	Frontiers Media S.A 24-06-2021
Subjects:	apoptosis cervical squamous cell carcinoma fascin actin-bundling protein 1 head and neck squamous cell carcinoma Oncology PIK3CA
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Radiotherapy is one of the standard treatments for cervical cancer and head and neck cancer. However, the clinical efficacy of this treatment is limited by radioresistance. The discovery of effective prognostic biomarkers and the identification of new therapeutic targets have helped to overcome the problem of radioresistance. In this study, we show that in the context of PIK3CA mutation or amplification, high expression of fascin actin-bundling protein 1 (FSCN1) (using the median as the cut-off value) is associated with poor prognosis and radiotherapy response in cancer patients. Silencing FSCN1 enhances radiosensitivity and promotes apoptosis in cancer cells with PIK3CA alterations, and this process may be associated with the downregulation of YWHAZ. These results reveal that FSCN1 may be a key regulator of radioresistance and could be a potential target for improving radiotherapy efficacy in cervical cancer and head and neck cancer patients with PIK3CA alterations.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 This article was submitted to Cancer Genetics, a section of the journal Frontiers in Oncology Edited by: Pin Ju Chueh, National Chung Hsing University, Taiwan These authors have contributed equally to this work Reviewed by: Luigi Minafra, National Research Council, Italy; Michael Abend, Bundeswehr Institute of Radiobiology Affiliated to the University Ulm, Germany; Wei Gao, First Hospital of Shanxi Medical University, China
ISSN:	2234-943X 2234-943X
DOI:	10.3389/fonc.2021.653005